ABCL
Income statement / Annual
Last year (2025), AbCellera Biologics Inc's total revenue was $75.13 M,
an increase of 160.56% from the previous year.
In 2025, AbCellera Biologics Inc's net income was -$146.41 M.
See AbCellera Biologics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$75.13 M |
$28.83 M |
$38.03 M |
$485.42 M |
$375.20 M |
$233.16 M |
$11.61 M |
$8.83 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$66.44 M
|
$45.52 M
|
$27.14 M
|
$0.00
|
$0.00
|
| Gross Profit |
$75.13 M
|
$28.83 M
|
$38.03 M
|
$418.99 M
|
$329.69 M
|
$206.01 M
|
$11.61 M
|
$8.83 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
0.86
|
0.88
|
0.88
|
1
|
1
|
| Research and Development Expenses |
$186.83 M
|
$167.26 M
|
$175.66 M
|
$107.88 M
|
$62.06 M
|
$29.39 M
|
$10.11 M
|
$5.80 M
|
| General & Administrative Expenses |
$0.00
|
$72.71 M
|
$61.00 M
|
$55.49 M
|
$41.85 M
|
$11.91 M
|
$2.75 M
|
$2.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$12.78 M
|
$14.18 M
|
$11.27 M
|
$6.91 M
|
$3.84 M
|
$1.26 M
|
$712.00 K
|
| Selling, General & Administrative Expenses |
$83.23 M
|
$85.49 M
|
$75.18 M
|
$66.76 M
|
$48.76 M
|
$15.75 M
|
$4.01 M
|
$2.86 M
|
| Other Expenses |
$22.17 M
|
$90.85 M
|
$24.40 M
|
$27.84 M
|
$14.45 M
|
$4.84 M
|
$1.60 M
|
$918.00 K
|
| Operating Expenses |
$292.23 M
|
$343.60 M
|
$275.23 M
|
$202.48 M
|
$125.27 M
|
$49.98 M
|
$15.73 M
|
$9.58 M
|
| Cost And Expenses |
$292.23 M
|
$343.60 M
|
$275.23 M
|
$268.91 M
|
$170.79 M
|
$77.12 M
|
$15.73 M
|
$9.58 M
|
| Interest Income |
$28.33 M
|
$38.47 M
|
$42.25 M
|
$16.08 M
|
$3.33 M
|
$293.00 K
|
$155.00 K
|
$42.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$4.05 M
|
$5.23 M
|
$6.51 M
|
$209.00 K
|
$212.00 K
|
| Depreciation & Amortization |
$22.17 M
|
$97.00 M
|
$30.89 M
|
$33.10 M
|
$17.25 M
|
$5.27 M
|
$1.85 M
|
$918.00 K
|
| EBITDA |
-$155.42 M |
-$204.15 M |
-$192.16 M |
$260.17 M |
$239.15 M |
$169.62 M |
-$155.00 K |
$1.44 M |
| EBITDA Ratio |
-2.07
|
-7.08
|
-5.05
|
0.54
|
0.64
|
0.73
|
-0.01
|
0.16
|
| Operating Income Ratio |
-2.89
|
-10.92
|
-6.24
|
0.45
|
0.54
|
0.67
|
-0.35
|
-0.09
|
| Total Other Income/Expenses Net |
$39.51 M
|
$114.37 M
|
$63.18 M
|
$22.59 M
|
$14.74 M
|
$1.80 M
|
$1.91 M
|
$1.06 M
|
| Income Before Tax |
-$177.60 M
|
-$200.40 M
|
-$174.03 M
|
$239.10 M
|
$219.15 M
|
$157.83 M
|
-$2.21 M
|
$309.00 K
|
| Income Before Tax Ratio |
-2.36
|
-6.95
|
-4.58
|
0.49
|
0.58
|
0.68
|
-0.19
|
0.03
|
| Income Tax Expense |
-$31.18 M
|
-$37.54 M
|
-$27.63 M
|
$80.58 M
|
$65.69 M
|
$38.92 M
|
$0.00
|
$0.00
|
| Net Income |
-$146.41 M
|
-$162.86 M
|
-$146.40 M
|
$158.52 M
|
$153.46 M
|
$118.92 M
|
-$2.21 M
|
$309.00 K
|
| Net Income Ratio |
-1.95
|
-5.65
|
-3.85
|
0.33
|
0.41
|
0.51
|
-0.19
|
0.03
|
| EPS |
-0.49 |
-0.55 |
-0.51 |
0.56 |
0.56 |
0.32 |
-0.0103 |
0.002 |
| EPS Diluted |
-0.49 |
-0.55 |
-0.51 |
0.5 |
0.48 |
0.45 |
-0.0103 |
0.002 |
| Weighted Average Shares Out |
$298.71 M
|
$294.33 M
|
$289.17 M
|
$285.06 M
|
$275.76 M
|
$267.82 M
|
$215.41 M
|
$151.06 M
|
| Weighted Average Shares Out Diluted |
$298.71 M
|
$294.33 M
|
$289.17 M
|
$314.83 M
|
$318.29 M
|
$263.13 M
|
$237.72 M
|
$151.04 M
|
| Link |
|
|
|
|
|
|
|
|
